Extended Data Table 3 Immunoglobulin titers for RCT patients

From: BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial

  1. Measurements were taken at SCR (n = 33), placebo at month 3 (n = 15), and Descartes-08 at month 3 (n = 19), and month 12 (n = 13). Table shows median and range. Immunoglobulin titers did not decrease from SCR in either placebo or Descartes-08 cohorts at any timepoints analyzed.
Back to article page